Tonix Pharmaceuticals filed a patent infringement lawsuit against Dr. Reddy’s Laboratories in the U.S. District Court for the District of New Jersey following a Paragraph IV certification regarding TONMYA®. The filing of the complaint triggers a statutory 30-month stay of final FDA approval for Dr. Reddy’s proposed generic version of the drug. Tonix seeks to prevent generic competition until the expiration of its Orange Book-listed patents.
Tonix Pharmaceuticals received a Paragraph IV patent certification notice from Dr. Reddy’s Laboratories (DRL) regarding an Abbreviated New Drug Application (ANDA) for a generic version of TONMYA®. DRL claims that four of Tonix's Orange Book-listed patents are invalid, unenforceable, or not infringed. Tonix intends to vigorously enforce its intellectual property rights, which could trigger an automatic 30-month stay of FDA approval for the generic product.
Counterparty
Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc.